Patient Pathway Pharmacist - Optimal Drug-related Care
Tracking Information | |||
---|---|---|---|
First Submitted Date ICMJE | September 11, 2018 | ||
First Posted Date ICMJE | October 3, 2018 | ||
Last Update Posted Date | October 3, 2018 | ||
Actual Study Start Date ICMJE | September 3, 2018 | ||
Estimated Primary Completion Date | February 15, 2019 (Final data collection date for primary outcome measure) | ||
Current Primary Outcome Measures ICMJE |
Discharge summary score[ Time Frame: At discharge (estimated five days after fracture/inclusion) ] In the discharge summary, the section describing drugs is scored in accordance with the national patient safety program Admission summary score[ Time Frame: At hospital admission (estimated to be within 24 hours after fracture) ] In the admission summary, the section describing drugs is scored. The score is adjusted from the discharge summary score to fit the admission note. Discharge summaries written in accordance with procedure[ Time Frame: At discharge (estimated five days after fracture/inclusion) ] In the discharge summary, the section describing drugs should be in accordance with procedure. Number of inappropriate drugs at discharge[ Time Frame: During hospitalisation, after surgery (estimated to be within five days after fracture/inclusion) ] After surgery the medication review may reduce the number of inappropriate drugs (on the STOPP-list). |
||
Original Primary Outcome Measures ICMJE | Same as current | ||
Current Secondary Outcome Measures ICMJE |
|
||
Descriptive Information | |||
Brief Title ICMJE | Patient Pathway Pharmacist - Optimal Drug-related Care |
||
Official Title ICMJE | Patient Pathway Pharmacist: Drug Optimisation for Hip Fracture Patients - Facilitating a Safe Patient Handover: a Descriptive Study |
||
Brief Summary | Medication errors represent the most common cause of patient injury and one of the most frequently reported health related deviation in Norway. The addition of a dedicated clinical pharmacist throughout the hip fracture patient pathway (patient pathway pharmacist) is believed to improve patient safety and ensure optimal drug-related patient care. The pharmacist will perform medication reconciliation at admission to hospital, medication review after surgery and assist physicians with discharge summary. Six weeks after discharge the patient pathway pharmacist will perform a second drug reconciliation and medication review. This study will assess the pharmacists' place and specific tasks in the patient pathway, describe areas where the pharmacist contribute to increased quality of care and assess the benefits and/or disadvantages experienced with introducing a patient pathway pharmacist. The estimated number of patients included is 60. Current practice will be determined by investigating the last 50 patients' medical record and a questionnaire to health care professionals involved in treatment of hip fracture patients. Data from medication reconciliation and drug review will be collected and compared to current practice. After the inclusion period, focus group surveys and/or semi-structured interviews will be executed to describe the perceived improvement in the quality of care. Primary endpoints are: 1) Medication reconciliation score at admission 2) Number of inappropriate drugs for elderly 3) Discharge summary score 4) Discharge summaries following procedure. Secondary endpoints are readmissions and mortality after 30 and 90 days. Qualitative endpoints: 1) Health care professionals experience of current drug-related practice 2) Experienced advantages and disadvantages of a patient pathway pharmacist. |
||
Detailed Description | |||
Study Type ICMJE | Interventional | ||
Study Phase | N/A | ||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Intervention Model Description: An intervention group is compared to a cross-sectional retrospective group. A group of 60 patients with hip fracture will get an intervention by a clinical pharmacist who performs medication reconciliation and medication review during hospitalisation, they will receive a discharge summary where the medication part is optimised. After six weeks the patients will be get a follow-up with a second medication reconciliation and - review. This group will be compared with the last 50 patients with hip fracture who did not get the intervention. Masking: Interventional Masking Description: Primary Purpose: Supportive Care |
||
Condition ICMJE | |||
Intervention ICMJE |
|
||
Study Arms |
|
||
Recruitment Information | |||
Recruitment Status ICMJE | Recruiting | ||
Estimated Enrollment ICMJE |
60 | ||
Original Estimated Enrollment ICMJE | Same as current | ||
Estimated Study Completion Date | March 30, 2019 | ||
Estimated Primary Completion Date | February 15, 2019 (Final data collection date for primary outcome measure) | ||
Eligibility Criteria ICMJE | Inclusion Criteria: - Hip fracture patients in Vestfold county, Norway Exclusion Criteria: - Patients under 18 years - Terminally ill - Hip fracture patients who do not follow the standardized patient pathway at Vestfold Regional Hospital - Patients who do not consent to be included in the study | ||
Sex/Gender |
|
||
Ages | 18 Years and older (Adult, Older Adult) | ||
Accepts Healthy Volunteers | No | ||
Listed Location Countries ICMJE | Norway | ||
Removed Location Countries | |||
Administrative Information | Has Data Monitoring Committee | No | |
U.S. FDA-regulated Product |
Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No |
||
IPD Sharing Statement |
|
||
Responsible Party | Ben Tore Henriksen,Sykehuset i Vestfold HF | ||
Study Sponsor ICMJE | Sykehuset i Vestfold HF | ||
Collaborators ICMJE | |||
Investigators ICMJE |
|
||
PRS Account | Sykehuset i Vestfold HF | ||
Verification Date | October 2018 | ||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |